And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is likely to be modest. We plan to celebrate another turning of the calendar with Mrs. Pharmalot, catch up on our reading, and schedule a few needed naps. And what about you? This is a fine time to enjoy the great outdoors, assuming you can keep your distance from other humans. Those of you on this side of the pond could prepare your taxes, since the treasury could use the money. Or you could reach out to someone feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

Johnson & Johnson (JNJ) has applied to the Food and Drug Administration for an emergency use authorization for its one-dose Covid-19 vaccine, setting in motion a process that is all but sure to see a third such vaccine authorized, STAT explains. If given the green light by the agency, the J&J vaccine will likely start being used in late February or early March, though initial supplies are expected to be extremely limited. The single dose makes it easier to deliver, as does the fact that the vaccine can be shipped and stored at refrigerator temperature.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]